Corus CAD

Latest Headlines

Latest Headlines

CardioDx CAD Dx passes another post-marketing test

CardioDx is promoting yet another post-marketing study whose data may help the company's gene expression test for obstructive coronary artery disease reach more patients, better compete with the standard of care build and also build vital market share.

CardioDx pulls in $58M to expand Dx commercial sales

CardioDx, a cardiovascular genomic diagnostics company, pulled in an impressive $58 million in new equity financing in a massive round that attracted a Singapore investment firm and lured 14 previous backers.

Study: Corus CAD demonstrates superiority to MPI

CardioDx saw good news from Florida this week with the presentation of results from the COMPASS trial involving Corus CAD, a blood-based gene expression test for obstructive coronary artery disease.